Najat Khan sold $202k of RXRX
Chief R&D Commercial Officer at RECURSION PHARMACEUTICALS, INC.. 36,599 shares at an average of $5.52, traded Aug 18, 2025, filed Aug 19, 2025.
Score components
- +15RoleOfficer
- +12Trade size$202k at market
- 0Share of holdings soldSold 5.2% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001601830-25-000131, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 15, 2025 | FTax withholding Class A Common Stock | -3,789 | $5.64 | $21k | 704,796 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Class A Common Stock | -36,599 | $5.52 | $202k | 668,197 | Aug 19, 2025 |
Related signals
Other insiders at RECURSION PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 16Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $242k 50,000 shares | -1% | |
| 3Weak | RECURSION PHARMACEUTICALS, INC. | Robert Hershberg director | $125k 25,000 shares | -13% | |
| 22Weak | RECURSION PHARMACEUTICALS, INC. | Najat Khan CEO and President | $79k 22,408 shares | -1% | |
| 13Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $100k 30,000 shares | -0% | |
| 26Weak | RECURSION PHARMACEUTICALS, INC. | Ben R Taylor Chief Financial Officer | $89k 21,383 shares | -3% | |
| 34Weak | RECURSION PHARMACEUTICALS, INC. | Najat Khan Chief R&D Commercial Officer | $549k 124,403 shares | -17% | |
| 32Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $180k 40,000 shares | -4% | |
| 25Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $185k 40,000 shares | -4% | |
| 27Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $961k 220,000 shares | -3% | |
| 24Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $166k 40,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.